Molecular Characterization of Ebselen Binding Activity to SARS-CoV-2 Main Protease
Cintia A. Menendez, Fabian Bylehn, Gustavo R. Perez-Lemus, Walter, Alvarado, Juan J. de Pablo

TL;DR
This study uses molecular simulations to analyze how Ebselen binds to SARS-CoV-2 main protease, revealing a new binding site and potential allosteric effects that could inform drug design against COVID-19.
Contribution
It uncovers a second, stronger binding site for Ebselen on Mpro and elucidates its allosteric effects, advancing understanding of its inhibitory mechanism.
Findings
Ebselen binds strongly to a newly identified site on Mpro.
A second binding site exhibits higher affinity than the catalytic site.
Binding induces allosteric changes that may inhibit enzymatic activity.
Abstract
The Coronavirus Disease (COVID-19) pandemic caused by the SARS-coronavirus 2 (SARS-CoV-2) urgently calls for the design of drugs directed against this new virus. Given its essential role in proteolytic processing, the main protease Mpro has been identified as an attractive candidate for drugs against SARS-CoV-2 and similar coronaviruses. Recent high-throughput screening studies have identified a set of existing, small-molecule drugs as potent Mpro inhibitors. Amongst these, Ebselen (2-Phenyl-1,2-benzoselenazol-3-one), a glutathione peroxidase mimetic seleno-organic compound, is particularly attractive. Recent experiments suggest that its effectiveness is higher than that of other molecules that also act at the enzyme catalytic site. By relying on extensive simulations with all-atom models, in this study we examine at a molecular level the potential of Ebselen to decrease Mpro catalytic…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
